Replies to post #2766 on NorthWest Biotherapeutics Inc (NWBO)

[longtermthinker]

I would say toss out the preclinical data
when valuing this thing
IMUC failure places significant doubt
on this type of therapy (it too had some impressive early trial results).
Phase III, as we have seen over and over again
with this type of treatment, usually proves
that Phase I and II results were merely teasers
without sufficient depth of sampling or proper
measurement of preconditions and end results
Holding my position in this stock because
I believe the science is nearly there.
Perhaps not quite, however. And perhaps
NWBO also goes down in flames, and also perhaps,
only to rise with modification of the therapy
agents. This is no lottery ticket. Seems to me
that given the crash and burn of IMUC, NWBO
can only move forward with signficant Phase III outcomes
and perhaps, only with full or partial approval from the fda.
But make no mistake, the IMUC failure IS important to NWBO
shareholders.

[flipper44]

In today's speech, Linda stated the RECIST criteria was 25% shrinkage (not 30%). This is also good news.